Ceftriaxone and Busulfan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ceftriaxone (ceftriaxone sodium) and Busulfan (busulfan). Common drug interactions include gastrointestinal inflammation among females and pulmonary hypertension among males.

The phase IV clinical study analyzes what interactions people have when they take Ceftriaxone and Busulfan. It is created by eHealthMe based on reports of 39 people who take the same drugs from the FDA, and is updated regularly.

What is Ceftriaxone?

Ceftriaxone has active ingredients of ceftriaxone sodium. It is often used in typhoid fever. eHealthMe is studying from 40,991 Ceftriaxone users. Check the latest studies of Ceftriaxone.

What is Busulfan?

Busulfan has active ingredients of busulfan. eHealthMe is studying from 14,527 Busulfan users. Check the latest studies of Busulfan.



On Jul, 22, 2026

39 people who take Ceftriaxone and Busulfan together, and have interactions are studied.

Ceftriaxone and Busulfan drug interactions.

What are the common drug interactions of Ceftriaxone and Busulfan, by gender? *:

female:

  1. Gastrointestinal inflammation (inflammation of stomach and intestine)
  2. General physical health deterioration (weak health status)
  3. Genital haemorrhage (bleeding from genital)
  4. Headache (pain in head)
  5. Heart rate increased
  6. Hepatic failure (liver failure)
  7. Hepatic pain (pain in liver)
  8. Hypertension (high blood pressure)
  9. Hypertransaminasaemia
  10. Hypoxia (low oxygen in tissues)

male:

  1. Pulmonary hypertension (increase in blood pressure in the lung artery)
  2. Restrictive cardiomyopathy (a condition in which the walls of the lower chambers of the heart (the ventricles) are abnormally rigid and lack the flexibility)
  3. Cytomegalovirus infection
  4. Febrile neutropenia (fever with reduced white blood cells)
  5. Leukaemia (blood or bone marrow cancer)
  6. Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)
  7. Acute graft versus host disease in intestine (acute complication in intestine following an allogeneic tissue/blood transplant)
  8. Acute lymphocytic leukaemia (cancer of the white blood cells)
  9. Acute myeloid leukaemia recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent)
  10. Blood creatine phosphokinase increased

What are the common drug interactions of Ceftriaxone and Busulfan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

  1. Pulmonary hypertension (increase in blood pressure in the lung artery)
  2. Restrictive cardiomyopathy (a condition in which the walls of the lower chambers of the heart (the ventricles) are abnormally rigid and lack the flexibility)
  3. Heart transplant
  4. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
  5. Deep vein thrombosis (blood clot in a major vein that usually develops in the legs and/or pelvis)
  6. Febrile neutropenia (fever with reduced white blood cells)
  7. Fungal infection
  8. Idiopathic pneumonia syndrome (pneumonia-like symptoms)
  9. Metapneumovirus infection (infection with human metapneumovirus)
  10. Mucosal inflammation (infection of mucous membrane)

10-19:

  1. Arthralgia (joint pain)
  2. Back pain
  3. Osteonecrosis (death of bone)
  4. Osteoporosis (bones weak and more likely to break)

20-29:

  1. Adenoviral haemorrhagic cystitis
  2. Clostridium difficile colitis (inflammation of colon by clostridium difficile bacteria infection)
  3. Cytomegalovirus infection
  4. Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)
  5. Acute graft versus host disease in intestine (acute complication in intestine following an allogeneic tissue/blood transplant)
  6. Acute graft versus host disease in skin (acute complication on skin following an allogeneic tissue/blood transplant)
  7. Abdominal pain lower
  8. Acute myeloid leukaemia recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent)
  9. Central nervous system infection (infection of brain or spinal cord)
  10. Device expulsion

30-39:

  1. Hepatic failure (liver failure)
  2. Hypertransaminasaemia
  3. Jaundice (a yellowish pigmentation of the skin, the conjunctival membranes)
  4. Lung abscess (pus in lungs)
  5. Mucosal inflammation (infection of mucous membrane)
  6. Nausea (feeling of having an urge to vomit)
  7. Nervous system disorder (a general class of medical conditions affecting the nervous system)
  8. Pneumonia
  9. Productive cough
  10. Pulmonary fibrosis (formation or development of excess fibrous connective tissue (fibrosis) in the lungs)

40-49:

  1. Arthralgia (joint pain)
  2. Asthenia (weakness)
  3. Diarrhoea
  4. Dizziness
  5. Dysphagia (a condition in which swallowing is difficult or painful)
  6. Dyspnoea (difficult or laboured respiration)
  7. Ear haemorrhage (bleeding from ear)
  8. Fatigue (feeling of tiredness)
  9. Flushing (the warm, red condition of human skin)
  10. Gait disturbance

50-59:

  1. Acute graft versus host disease in intestine (acute complication in intestine following an allogeneic tissue/blood transplant)
  2. Acute graft versus host disease in skin (acute complication on skin following an allogeneic tissue/blood transplant)
  3. Acute myeloid leukaemia recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent)
  4. Adenoviral haemorrhagic cystitis
  5. Balance disorder
  6. Bladder disorder
  7. Blood creatine phosphokinase increased
  8. Bone disorder
  9. Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
  10. Bronchopulmonary aspergillosis (lung disorder caused by aspergillus fungi)

60+:

  1. Cerebral haemorrhage (bleeding within the brain)
  2. Chills (felling of cold)
  3. Acute graft versus host disease in liver (acute complication in liver following an allogeneic tissue/blood transplant)
  4. Acute graft versus host disease in skin (acute complication on skin following an allogeneic tissue/blood transplant)
  5. Acute lymphocytic leukaemia (cancer of the white blood cells)
  6. Altered state of consciousness (altered state of mind)
  7. Arrhythmia (irregular heartbeat)
  8. Cardio-respiratory arrest (sudden dysfunction of heart and lungs)
  9. Clostridial infection (infectious conditions by clostridium bacteria)
  10. Cytomegalovirus test positive

What are the existing conditions these people have? *

  1. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 14 people, 35.90%
  2. Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 8 people, 20.51%
  3. Bone Marrow Conditioning Regimen: 8 people, 20.51%
  4. Pain: 4 people, 10.26%
  5. Nausea (feeling of having an urge to vomit): 4 people, 10.26%
  6. Constipation: 4 people, 10.26%
  7. Multiple Myeloma (cancer of the plasma cells): 4 people, 10.26%
  8. Viral Upper Respiratory Tract Infection: 3 people, 7.69%
  9. Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 7.69%
  10. Fever: 3 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftriaxone and Busulfan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ceftriaxone and Busulfan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ceftriaxone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Busulfan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ceftriaxone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Busulfan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on ceftriaxone sodium and busulfan (the active ingredients of Ceftriaxone and Busulfan, respectively), and Ceftriaxone and Busulfan (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: